Skip to main content
    B

    BioNexus Gene Lab Corp Common stock (BGLC)

    Official site

    BASIC MATERIALS • SPECIALTY CHEMICALS • NASDAQ

    $0.77
    -0.05 (-6.56%)

    Market Cap: $2.41M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    BioNexus Gene Lab Corp Common stock (BGLC) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    BioNexus Gene Lab Corp Common stock (BGLC) has a market cap of $2.41M and an enterprise value of $1.17M. Its share count is up 63.28% from a year earlier. It kept -84.93% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 51.25% below the market cap, as cash exceeds debt.

    Market Cap$2.41M
    Enterprise Value$1.17M
    Latest price (Nov 17, 2026)$0.77

    Key Dates

    Last Earnings DateAug 14, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 21.35% in the quarter ended Jun 30, 2026 and shrank 59.25% a year over 2 years.

    Shares Outstanding2.93M
    Shares Change (YoY)+63.28%
    Shares Change (QoQ)+21.35%
    Share Count Growth (2Y CAGR)-59.25%

    Price Statistics

    The stock is down 83.09% over 52 weeks and trades 35.83% below its 50-day average.

    Beta (1Y)1.55
    52-Week Change-83.09%
    1-Month Change-37.60%
    3-Month Change-51.20%
    6-Month Change-63.51%
    5-Year Change-99.60%
    Total Return (1Y)-83.09%
    Total Return (3Y CAGR)-38.53%
    Total Return (5Y CAGR)-68.12%
    Max Drawdown (1Y)-84.07%
    Max Drawdown (3Y)-95.12%
    Sharpe Ratio (1Y)-2.57
    Correlation with SPY (1Y)0.30
    50-Day Average$1.20
    200-Day Average$1.83
    52-Week Range$0.80 to $4.97
    RSI (14 Days)30.8
    Average Volume (20 Days)6.33K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 6.08x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio6.08x
    Quick Ratio5.28x
    Debt / Equity0.00x
    Interest Coverage-136.85x

    Returns and Efficiency

    Return on equity is -34.14% over the last 12 months, against a 5-year average of -15.19%.

    Return on Equity (ROE)-34.14%
    Return on Assets (ROA)-30.43%
    Return on Capital Employed (ROCE)-31.45%
    ROE (5Y Average)-15.19%
    ROA (5Y Average)-13.37%
    ROIC (5Y Average)-25.78%
    Asset Turnover0.34x
    Inventory Turnover4.00x
    Receivables Turnover21.32x
    Cash Conversion Cycle25 days

    Scores

    BGLC has an Altman Z-Score of 0.24, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score0.24
    Altman Z ZoneDistress
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $3.13M over the last 12 months is down 67.27% from the 12 months before.

    Revenue$3.13M
    Revenue Growth (YoY)-67.27%
    Gross Profit$385.89K
    Operating Income-$2.56M
    Pretax Income-$2.58M
    Net Income-$2.66M
    EBITDA-$2.31M
    EBIT-$2.49M
    Reported EPS (TTM)-$1.27

    Trailing 12 months through Jun 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 89.12% of the $8.73M in total assets.

    Cash and Equivalents$1.23M
    Total Debt$0
    Net Cash$1.23M
    Net Cash Per Share$0.42
    Working Capital$4.13M
    Shareholder Equity$7.78M
    Total Assets$8.73M
    Total Liabilities$947.98K

    Balance sheet as of Jun 30, 2026.

    Full balance sheet

    Cash Flow

    After $7.04K of capital spending, operating cash flow left -$853.60K of free cash flow.

    Operating Cash Flow-$846.57K
    Capital Expenditures$7.04K
    Free Cash Flow-$853.60K
    FCF Per Share-$0.29
    Depreciation and Amortization$176.83K

    Trailing 12 months through Jun 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -81.82%, against a 5-year average of -15.56%.

    Gross Margin12.34%
    Operating Margin-81.82%
    Pretax Margin-82.36%
    Net Margin-84.93%
    EBITDA Margin-73.94%
    EBIT Margin-79.60%
    FCF Margin-27.30%
    Gross Margin (5Y Average)14.05%
    Operating Margin (5Y Average)-15.56%
    Net Margin (5Y Average)-16.31%

    Growth

    Revenue fell 12.09% a year over 3 years.

    Revenue Growth (3Y CAGR)-12.09%
    Revenue Growth (5Y CAGR)-8.20%

    Revenue and profit by year

    Dividends and Yields

    BGLC does not pay a dividend. Its free cash flow yield is -37.98%.

    FCF Yield-37.98%
    Shareholder Yield0.00%

    Stock Splits

    The last split was a 1-for-10 reverse split on Apr 7, 2025.

    Last Split DateApr 7, 2025
    Split TypeReverse split
    Split Ratio1:10

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About BGLC

    What is BGLC's market cap?

    BioNexus Gene Lab Corp Common stock has a market cap of $2.41M. Its enterprise value, which adds debt and subtracts cash, is $1.17M.

    How many shares of BGLC are outstanding?

    BioNexus Gene Lab Corp Common stock has 2.93M shares outstanding. The count is up 63.28% from a year earlier.

    Does BGLC pay a dividend?

    No. BioNexus Gene Lab Corp Common stock does not pay a dividend.

    How much debt does BGLC have?

    BioNexus Gene Lab Corp Common stock has $0 of total debt and $1.23M of cash and equivalents, a net cash position of $1.23M.